myelodysplastic syndromes (MDS) | Page 9 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Infectious complications in patients with myelodysplastic syndromes: a review of the literature with emphasis on patients treated with 5-azacitidine

Author(s): 
Radsak M, Platzbecker U, Schmidt CS, Hofmann WK, Nolte F
Primary Author: 
Radsak M
Journal Title: 
Eur J Haematol
Original Publication Date: 
Mar 2017

Bone Marrow Diseases: 

Allogeneic Hematopoietic Stem Cell Transplantation is Underutilized in Older Patients with Myelodysplastic Syndromes

Author(s): 
Getta BM, Kishtagari A, Hilden P, Tallman MS, Maloy M, Gonzales P, Castro-Malaspina H, Perales MA, Giralt S, Tamari R, Klimek V
Primary Author: 
Getta BM
Journal Title: 
Biol Blood Marrow Transplant
Original Publication Date: 
Mar 2017

Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative treatment for myelodysplastic syndrome (MDS). The proportion of MDS patients referred for transplant evaluation, those undergoing transplantation and the reasons for not undergoing transplant are unknown. In this retrospective analysis, pre-defined HCT eligibility and indications criteria were applied to 362 unselected patients with newly diagnosed MDS seen by Leukemia faculty between 2008 and 2015 at Memorial Sloan Kettering Cancer Center.

Bone Marrow Diseases: 

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Author(s): 
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F
Primary Author: 
Park S
Journal Title: 
J Clin Oncol
Original Publication Date: 
Mar 2017

Purpose Most anemic patients with non-deleted 5q lower-risk

Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years

Author(s): 
Lyons RM, Marek BJ, Paley C, Esposito J, McNamara K, Richards PD, DiBella N, Garcia-Manero G.
Primary Author: 
Lyons RM
Journal Title: 
Leuk Res
Original Publication Date: 
Jan 2017

Prospective data are needed to ascertain the impact of

Bone Marrow Diseases: 

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome

Author(s): 
de Montalembert M, Ribeil JA, Brousse V, Guerci-Bresler A, Stamatoullas A, Vannier JP, Dumesnil C, Lahary A, Touati M, Bouabdallah K, Cavazzana M, Chauzit E, Baptiste A, Lefebvre T, Puy H, Elie C, Karim Z, Ernst O, Rose C
Primary Author: 
de Montalembert M
Journal Title: 
PLoS One
Original Publication Date: 
Mar 2017

The risk and clinical significance of cardiac

Bone Marrow Diseases: 

Focal Adhesion Kinase as a Potential Target in AML and MDS

Author(s): 
Carter BZ, Mak PY, Wang X, Yang H, Garcia-Manero G, Mak D, Mu H, Ruvolo V, Qiu Y, Coombes K, Zhang N, Ragon B, Weaver DT, Pachter JA, Kornblau S, Andreeff M
Primary Author: 
Carter BZ
Journal Title: 
Mol Cancer Ther
Original Publication Date: 
Mar 2017

Although overexpression/activation of focal adhesion kinase (FAK) is widely known in solid tumors to control cell growth, survival, invasion, metastasis, gene expression, and stem cell self-renewal, its expression and function in myeloid leukemia are not well investigated.

Bone Marrow Diseases: 

Self-reported sleep disturbance and survival in myelodysplastic syndromes

Author(s): 
Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA
Primary Author: 
Luskin MR
Journal Title: 
Br J Haematol
Original Publication Date: 
Mar 2017

Neither the prevalence of sleep disturbance nor its association with fatigue and overall survival (OS) are well understood for patients with

Bone Marrow Diseases: